Sells infusion consumables, infusion pumps and related software, and critical-care products to hospitals, clinics, distributors and other healthcare providers.
10-K for FY2025, filed Feb 19, 2026
Hospitals, distributors and other end customers generally pay for products, with most product sales paid within 30 days of delivery; the company sells most products when they ship. Software license renewals are paid at the start of each renewal period.
10-K for FY2025, filed Feb 19, 2026We recognize revenues when we transfer control of promised goods to our customers, which for the majority of our sales of products sold on…View ↗
Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that…View ↗
Our business units are Consumables, Infusion Systems and Vital Care. The vast majority of our sales of these products within these business…View ↗
10-K for FY2025, filed Feb 19, 2026
FY2025 revenue by product or service ↗$2.2B
10-K for FY2025, filed Feb 19, 2026
$2.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Infusion Consumables
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
50%
FY2022: 43%
|
Infusion Consumables, FY2025
$1.1B Sources
|
Sold outright |
|
Infusion Systems
Mix
10-K for FY2025, filed Feb 19, 2026 |
31%
FY2022: 27%
|
Infusion Systems, FY2025
$684.2M Sources
|
Mix |
|
Vital Care
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
20%
FY2022: 30%
|
Vital Care, FY2025
$437.9M Sources
|
Sold outright |
Hospitals and other healthcare providers, along with medical product manufacturers, buy directly or through independent medical-supply distributors. Distributors also resell products to healthcare providers.
10-K for FY2025, filed Feb 19, 2026
10-K for FY2025, filed Feb 19, 2026
We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and…View ↗
Yes. It kept less than a cent of every revenue dollar as net income in FY2025 and turned 4 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
$26.8MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Growing. Revenue grew 70% in 4 years, from $1.3B in FY2021 to $2.2B in FY2025, about 14% a year.
IV Solutions ownership and sales
The older report described IV solutions as part of the company’s product portfolio. The latest report says it transferred the business to a joint venture, sold a controlling interest to OPF, and sells and distributes its products for the joint venture.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 19, 2026ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications.…View ↗
Integrated product portfolio
The older report presented Smiths Medical products in separate sections while the company integrated that business. The latest report incorporates these products into its main product descriptions, including ambulatory and syringe pumps, vascular access, and vital care.
10-K for FY2025, filed Feb 19, 2026ICU develops, manufactures and sells innovative medical products used in infusion therapy, vascular access, and vital care applications.…View ↗
We offer a comprehensive portfolio of infusion pumps, dedicated IV sets, software and professional services to meet the wide range of…View ↗
Our Vital Care business unit includes IV Solutions, Hemodynamic Monitoring, General Anesthesia and Respiratory, Temperature Management…View ↗
Competes with Becton Dickinson, Baxter International, B. Braun Medical, Angiodynamics, Teleflex, EquaShield, Medtronic, Moog Medical, Fresenius Kabi, Fresenius, Edwards Lifesciences, Belmont, Medical Technologies, and Intersurgical
10-K for FY2025, filed Feb 19, 2026We believe that our ability to effectively compete in the Consumables market depends upon our ability to differentiate our products based…View ↗
Loading...